{"drugs":["Macugen","Pegaptanib Octasodium"],"mono":{"0":{"id":"928352-s-0","title":"Generic Names","mono":"Pegaptanib Octasodium"},"1":{"id":"928352-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928352-s-1-4","title":"Adult Dosing","mono":"<b>Age related macular degeneration, Neovascular (Wet):<\/b> 0.3 mg by INTRAVITREOUS INJECTION once every 6 weeks; adequate anesthesia and a broad-spectrum antibiotic should be given prior to injection "},"1":{"id":"928352-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatric patients have not been established "},"3":{"id":"928352-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Age related macular degeneration, Neovascular (Wet)<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Diabetic macular edema<br\/>"}}},"3":{"id":"928352-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928352-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to pegaptanib or any other component of the formulation<\/li><li>ocular or periocular infections<\/li><\/ul>"},{"id":"928352-s-3-10","title":"Precautions","mono":"<ul><li>anaphylactoid\/anaphylactic reactions, including angioedema; cases have been reported in post-marketing<\/li><li>endophthalmitis has been associated with intravitreous injections<\/li><li>increase in intraocular pressure; has been observed within 30 minutes of injection<\/li><li>ophthalmic intravitreal injection only<\/li><\/ul>"},{"id":"928352-s-3-11","title":"Pregnancy Category","mono":"Pegaptanib: B (FDA)<br\/>"},{"id":"928352-s-3-12","title":"Breast Feeding","mono":"Pegaptanib: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928352-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Corneal edema, Discharge from eye, Eye irritation, Pain in eye, Punctate keratitis, Raised intraocular pressure, Reduced visual acuity, Visual discomfort, Visual disturbance, Vitreous floaters, Vitreous opacities<br\/><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis (rare)<\/li><li><b>Ophthalmic:<\/b>Endophthalmitis, Retinal detachment, Traumatic cataract, Iatrogenic<\/li><\/ul>"},"6":{"id":"928352-s-6","title":"Drug Name Info","sub":{"0":{"id":"928352-s-6-17","title":"US Trade Names","mono":"Macugen<br\/>"},"2":{"id":"928352-s-6-19","title":"Class","mono":"Ophthalmologic Agent<br\/>"},"3":{"id":"928352-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928352-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928352-s-7","title":"Mechanism Of Action","mono":"Pegaptanib octasodium is a selective vascular endothelial growth factor (VEGF) inhibitor. It is a pegylated modified oligonucleotide, which adopts a three-dimensional shape that enables it to bind to extracellular VEGF(165), inhibiting binding to VEGF(165) receptors and thereby suppressing pathological neovascularization.<br\/>"},"8":{"id":"928352-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928352-s-8-23","title":"Absorption","mono":"Intravitreous: time to peak concentration, 1 day to 4 days <br\/>"},"4":{"id":"928352-s-8-27","title":"Elimination Half Life","mono":"10 days +\/- 4 days <br\/>"}}},"9":{"id":"928352-s-9","title":"Administration","mono":"<b>Intravitreal<\/b><br\/><ul><li>for ophthalmic intravitreal injection only<\/li><li>assemble syringe and included needle (or another equivalent needle) under aseptic conditions; do not use if plastic clip is missing or not attached to the syringe<\/li><li>force all bubbles out of syringe prior to use by depressing plunger so that the top edge of the 3rd rib on the plunger stopper aligns with the preprinted dosing line; do not shake syringe vigorously<\/li><li>adequate anesthesia and a broad-spectrum antibiotic should be given prior to injection; the injection procedure should be done under controlled aseptic conditions<\/li><li>safety and efficacy of administration to both eyes concurrently have not been established<\/li><\/ul>"},"10":{"id":"928352-s-10","title":"Monitoring","mono":"<ul><li>visual acuity; stability may indicate clinical efficacy<\/li><li>intraocular pressure; with tonometry within 30 minutes of injection, and the week following treatment<\/li><li>perfusion of the optic nerve head; immediately after injection, and the week following treatment<\/li><li>endophthalmitis; following treatment<\/li><li>eye infection; the week following treatment<\/li><\/ul>"},"11":{"id":"928352-s-11","title":"How Supplied","mono":"<b>Macugen<\/b><br\/>Intraocular Solution: 0.3 MG\/0.09 ML<br\/>"},"13":{"id":"928352-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause discharge, irritation, or dryness of the eye, visual discomfort\/disturbance, vitreous floaters\/opacities, or punctuate keratitis (eye pain, increased tearing, photophobia, eye redness, blurred vision).<\/li><li>Advise patient to immediately report signs\/symptoms of intraocular infection (eye redness, pain, sensitive to light, decreased visual acuity).<\/li><\/ul>"}}}